Goldman Sachs’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,048,297
| Closed | -$18.4M | – | 5746 |
|
|
2019
Q4 | $18.4M | Sell |
3,048,297
-3,133,885
| -51% | -$18.1M | ﹤0.01% | 1942 |
|
|
2019
Q3 | $22.3M | Sell |
6,182,182
-356,043
| -5% | -$1.37M | 0.01% | 1682 |
|
|
2019
Q2 | $17.5M | Sell |
6,538,225
-584,416
| -8% | -$1.73M | 0.01% | 1955 |
|
|
2019
Q1 | $21.1M | Buy |
7,122,641
+1,733,840
| +32% | +$4.26M | 0.01% | 1823 |
|
|
2018
Q4 | $8.57M | Buy |
5,388,801
+713,201
| +15% | +$2.02M | ﹤0.01% | 2453 |
|
|
2018
Q3 | $17.2M | Sell |
4,675,600
-468,343
| -9% | -$1.4M | ﹤0.01% | 2028 |
|
|
2018
Q2 | $14.6M | Sell |
5,143,943
-548,454
| -10% | -$1.87M | ﹤0.01% | 2127 |
|
|
2018
Q1 | $21.1M | Buy |
5,692,397
+2,690,283
| +90% | +$8.8M | 0.01% | 1820 |
|
|
2017
Q4 | $8.65M | Buy |
3,002,114
+295,376
| +11% | +$1.07M | ﹤0.01% | 2569 |
|
|
2017
Q3 | $12.2M | Sell |
2,706,738
-906,956
| -25% | -$4.03M | ﹤0.01% | 2404 |
|
|
2017
Q2 | $16.6M | Sell |
3,613,694
-111,973
| -3% | -$450K | ﹤0.01% | 2093 |
|
|
2017
Q1 | $15.7M | Sell |
3,725,667
-726,375
| -16% | -$3.02M | ﹤0.01% | 2065 |
|
|
2016
Q4 | $18.4M | Sell |
4,452,042
-1,047,198
| -19% | -$5.57M | 0.01% | 2020 |
|
|
2016
Q3 | $44.5M | Buy |
5,499,240
+1,520,505
| +38% | +$12.9M | 0.01% | 1296 |
|
|
2016
Q2 | $31M | Buy |
3,978,735
+1,388,241
| +54% | +$11.9M | 0.01% | 1458 |
|
|
2016
Q1 | $20M | Sell |
2,590,494
-37,954
| -1% | -$278K | 0.01% | 1715 |
|
|
2015
Q4 | $28.4M | Buy |
2,628,448
+358,020
| +16% | +$3.25M | 0.01% | 1502 |
|
|
2015
Q3 | $15.7M | Sell |
2,270,428
-254,816
| -10% | -$2.08M | 0.01% | 1900 |
|
|
2015
Q2 | $22.4M | Sell |
2,525,244
-635,363
| -20% | -$6.01M | 0.01% | 1703 |
|
|
2015
Q1 | $31.2M | Sell |
3,160,607
-2,105,133
| -40% | -$26.3M | 0.01% | 1446 |
|
|
2014
Q4 | $64.5M | Buy |
5,265,740
+1,652,636
| +46% | +$20.2M | 0.02% | 925 |
|
|
2014
Q3 | $36.1M | Buy |
3,613,104
+948,742
| +36% | +$8.81M | 0.01% | 1321 |
|
|
2014
Q2 | $20.2M | Buy |
2,664,362
+254,230
| +11% | +$1.01M | 0.01% | 1776 |
|
|
2014
Q1 | $7.93M | Buy |
2,410,132
+13,371
| +0.6% | +$46.8K | ﹤0.01% | 2565 |
|
|
2013
Q4 | $7.96M | Buy |
2,396,761
+124,721
| +5% | +$362K | ﹤0.01% | 2588 |
|
|
2013
Q3 | $6.86M | Buy |
2,272,040
+738,740
| +48% | +$5.06M | ﹤0.01% | 2618 |
|
|
2013
Q2 | $12.5M | Buy |
+1,533,300
| New | +$11.7M | ﹤0.01% | 1899 |
|
Goldman Sachs's ACHN Position: Q1 2020 in Review
Goldman Sachs sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,048,297 shares — an estimated $18.4M sold.
Goldman Sachs first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $64.5M in Q4 2014. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Goldman Sachs reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 3,048,297 Achillion Pharmaceuticals shares in Q1 2020, an estimated $18.4M.
- Goldman Sachs first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's Achillion Pharmaceuticals position peaked at $64.5M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.